Integrating cost-effectiveness evidence into clinical practice guidelines in Australia for acute myocardial infarction

European Journal of Health Economics

Volumn 3, Issue 1, 2002, Pages 26-39

  Antioch, Kathryn M ^a,b,c   Jennings, G ^a,b,d   Botti, M ^a,e   Chapman, R ^a   Wulfsohn, V ^a  

^a ALFRED HOSPITAL   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c BAYSIDE HEALTH   (Australia)

^d BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^e DEAKIN UNIVERSITY   (Australia)

Author keywords

Acute myocardial infarction; Clinical practice; Cost effectiveness; Guidelines

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ALTEPLASE; HEPARIN; TIROFIBAN;

ACUTE HEART INFARCTION; ANGIOPLASTY; ARTICLE; AUSTRALIA; COST EFFECTIVENESS ANALYSIS; DRUG COST; GOVERNMENT; HUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; TEACHING HOSPITAL; TRANSLUMINAL CORONARY ANGIOPLASTY;

EID: 0012647184     PISSN: 16187598     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10198-001-0088-z     Document Type: Article

References (62)

1. Adele C, Vaitkus PT, Wells SK, Zehnacker JB (1998) "Cost advantages of an ad hoc angioplasty strategy." J Am Coll Cardiol 31:321-325
2. Agency for Healthcare Research and Quality (1995) "Cardiac Rehabilitation"
3. American College of Cardiology/American Heart Association (1997) "Guidelines for exercise testing." A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Exercise Testing)
4. American College of Cardiology/American Heart Association (1999) "Guidelines" "for coronary angiography"
5. American College of Chest Physicians (1998) "Fifth ACCP Consensus Conference on Antithrombotic Therapy"
6. American College of Physicians/American Society of Internal Medicine (1996) "Coronary artery disease with myocardial infarction." Background paper, 22 April
7. American College of Radiology (1995) "Appropriateness criteria for acute chest pain, suspected myocardial ischemia"
8. Anderson FP, Fritz ML, Kontos MC, McPherson RA, Jesse RL (1998) "Cost effectiveness of cardiac troponin in a systematic chest pain evaluation protocol: use of cardiac troponin 1 lowers length of stay for low risk cardiac patients." Clin Lab Manage Rev 12(2):63-69
9. Antioch KM, Chapman R, Elliot B, Santamaria N, Crawford R, Fiddes K (2001) "Cost-effective clinical pathways at the Alfred Hospital: international lessons from Bayside Health." Aust Health Rev 24(4):21-29
10. Australian Institute of Health and Welfare (1998) " InternationalHealth. How Australia compares." AIHW catalogue No PHE-8
11. Cairns JA, Connolly SJ, Roberts R, et al For the Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators (1997) "Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT." Lancet 349:675-682
12. Canadian Task Force on Preventive Health Care (1998) "Physical activity counseling"
13. Cohen M, Demers C, Gurfinkel EP, et al (1997) "A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease: efficacy and safety of subcutaneous enoxaparin in non-Q-wave coronary events study group." N Engl J Med 337:447-452
14. Davey PJ, Schulz M, Gliksman M, Dobson M, Aristides M, Stephens NG (1998) "Cost-effectiveness of vitamin E therapy in the treatment of patients with angiographically proven coronary narrowing (CHAOS trial)." Cambridge Heart Antioxidant Study. Am J Cardiol 82(4):414-417
15. Drummond, MF O'Brien B, Stoddart GL, Torrance GW (1997) "Methods for the economic evaluation of health care programmes, 2nd edn." Oxford Medical Publications, Inc New York, USA
16. European Society of Cardiology (1998) "The pre-hospital management of acute heart attacks"
17. European Society of Cardiology, European Atherosclerosis Society, European Society of Hypertension, European Society of General Practice, Family Medicine, International Society of Behavioural Medicine and European Heart Network (1998) "Prevention of coronary heart disease in clinical practice"
18. Gibbons RJ, Holmes DR, Reeder GS, Bailey KR, Hopfenspirger MR, Gersh BJ (1993) "Immediate angioplasty compared with the administration of a thrombolytic agent followed by conservative treatment for myocardial infarction: the Mayo Coronary Care Unit and Catheterization Laboratory Groups." N Engl J Med 328:685-691
19. Gilman, JK, Jalal S, Naccarelli GV (1994) "Predicting and preventing sudden death from cardiac causes." Circulation 90:1083-1092
20. Gillum RF, Fortmann SP, Princeas RJ, et al (1984) "International diagnostic criteria for acute myocardial infarction and acute stroke." Am Heart J 108:150-158
21. Goklaney AK, Murphy JD, Hillegrass WB (1998) "Abciximab therapy in percutaneous intervention: economic issues in the United States." Am Heart J 135:590-597
22. Goodman S, Langer A, Demers C, et al (1998) "One year follow-up of the ESSENCE trial (enoxaparin vs heparin in unstable angina/non-Q wave myocardial infarction): sustained clinical benefit." Can J Cardiol 14:122F
23. Grines CL, Marsalese DL, Brodie B, Griffin J, Donohue B, Costantini CR, Balestrini C, Stone G, Wharton T, Esente P, Spain M, Moses J, Nobuyoshi M, Ayres M, Jones D, Mason D, Sachs D, Grines LL, O'Neill W (1998) "Safety and cost-effectiveness of early discharge after primary angioplasty in low risk patients with acute myocardial infarction.""PAMI-II investigators." "Primary Angioplasty in Myocardial Infarction." J Am Coll Cardiol 31(5):967-973
24. GUSTO Investigators (1993) "An international randomised trial comparing four thrombolytic strategies for acute myocardial infarction." N Engl J Med 329:673-682
25. Institute for Healthcare Quality (1998) "Quality" "FIRST coronary artery disease with myocardial infarction"
26. Julian DG, Camm A, Frangin G, et al for the European Myocardial Infarct Amiodarone Trial Investigators (1997) "Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction." EMIAT. Lancet 349:667-674
27. Kimmel SE, Berlin JA, Hennessy S, et al (1997) "Risk of major complications from coronary angioplasty performed immediately after diagnostic coronary angiography: results from the registry of the Society for Cardiac Angiography and Interventions." J Am Coll Cardiol 30:193-200
28. Lieu TA, Gurley RJ, Lundstrom RJ, et al (1996) "Primary angioplasty and thrombolysis for acute myocardial infarction: an evidence summary." J Am Coll Cardiol 27:737-750
29. Lonn EM, Yusuf S, Dzavik V, et al (2001) "Effects of Ramipril and vitamin E on atherosclerosis. The Study to Evaluate Carotid Ultrasound Changes in patients treated with Ramipril and Vitamin E (SECURE)." Am Heart Assoc 103:919-925
30. Lorenzoni R, Pagano D, Mazzotta G, Rosen SD, Fattore G, De Caterina R, Gensini G (1998) "Pitfalls in the economic evaluation of thrombolysis in myocardial infarction. The impact of national differences in the cost of thrombolytics and of differences in the efficacy across patient subgroups." Eur Heart J 19(10):1518-1524
31. Mark DB, Hlatky MA, Carliff RM, et al (1995) "Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction." N Engl J Med 332:1418-1424
32. Mark DB, Talley D, Topol EJ, et al (1996) "Economic assessment of platelet glycoprotein IIb/IIIa Inhibition for prevention of Ischemic complications of high-risk coronary angioplasty." Am Heart Assoc 94(4):629-635
33. Mark DB, Cowper PA, Berkowitz SD, Davidson-Ray L, DeLong ER, Turpie AGG, Califf RM, Weatherley B, Cohen M (1998) "Economic assessment of low-molecular-weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients - results from the ESSENCE randomised trial circulation." Circulation 97:1702-1707
34. Mark DB, Jalley JD, Jopol RJ, et al (1998) "Economic assessment of platelet glycoprotein IIb/IIIa inhibition for prevention of ischemic complications of high risk coronary angioplasty." Heart 79:12-17
35. Mullen M, Paulis M, Nikfardjam M, Domanovits H, Huber K (1999) "Primary PTCA versus thrombolysis with PA in acute myocardial infarction: a formal cost-effectiveness analysis." Wien Klin Wochenschr 111(1):37-41
36. National Health and Medical Research Council (1996) "Clinical practice guidelines for the procedural surgical management of coronary heart disease"
37. National Health and Medical Research Council (1996) "Angioplasty and bypass surgery - consumers' guide"
38. National Health and Medical Research Council (1999) "A guide to the development, implementation and evaluation of clinical practice guidelines"
39. National Health and Medical Research Council (2000) "How to use the evidence: assessment and application of scientific evidence. Handbook series on preparing clinical practice guidelines"
40. National Health and Medical Research Council (2001) "How to compare the costs and benefits: evaluation of the economic evidence." Handbook series on preparing clinical practice guidelines
41. Niessen LW, Grijseels EWM, Rutten FFH (2000) "The evidence based approach in health policy and health care delivery." Soc Sci Med 51:859-869
42. O'Brien BJ, Willan A, Blackhouse G, et al (2000) "Will the use of low-molecular-weight heparin (enoxaparin) in patients with acute coronary syndrome save costs in Canada?" Am Heart J 139:423-429
43. OECD (2000) "OECD health data comparative data of 29 countries"
44. O'Keefe JH, Gernon C, McCallister BD, et al (1991) "Safety and cost effectiveness of combined coronary angiography and angioplasty." Am Heart J 122:50-54
45. Pedretti RF, Migliori GB, Mapelli V, Daniele G, Podrid PJ, Tramarin R (1998) "Cost-effectiveness analysis of invasive and noninvasive tests in high risk patients treated with amiodarone after acute myocardial infarction." J Am Coll Cardiol 31(7):1481-1489
46. PRISM Investigators (1998) "A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina: Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) study investigators." N Engl J Med 338:1498-1505
47. PRISM-PLUS Investigators (1998) "Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) study investigators." N Engl J Med 338:1488-1497 (published erratum 339:415)
48. RESTORE Investigators (1997) "Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute Ml undergoing coronary angioplasty." Circulation 96:1445-1453
49. Rozeman Y, Gilon D, Zelinger J, et al (1995) "One-stage coronary angiography and angioplasty." Am J Cardiol 75:30-33
50. Ryan TJ, Anderson JL, Amman EM, et al (1996) "ACC/AHA guidelines for the management of patients with acute myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction)." J Am Coll Cardiol 28(5):1328-1428
51. Ryan TJ, Antman EM, Brooks NH, et al (1999) "ACC/AHA guidelines for the management of patients with acute myocardial infarction: 1999 update: a report of the American College of Cardiology/American Heart Association Task Force on Guidelines (Committee on Management of Acute Myocardial Infarction)." Web version
52. Ryan TJ, Antman EM, Brooks NH, et al (1999) "ACC/AHA guidelines for the management of patients with acute myocardial infarction: executive summary and recommendations: 1999 update: a report of the American College of Cardiology/American Heart Association Task Force on Guidelines (Committee on Management of Acute Myocardial Infarction)"
53. Scott NA, Weintraub WS, Carlin SF, et al (1993) "Recent changes in the management and outcome in acute closure after percutaneous transluminal coronary angioplasty." Am J Cardiol 71:1159-1163
54. Society of Nuclear Medicine (1999) "Procedure guidelines for myocardial perfusion imaging"
55. Stephens NG, Parsons A, Schofield PM, et al (1996) "Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS)." Lancet 347:781-786
56. Szucs TD, Meyer BJ, Kiowski W (1999) "Economic assessment of tirofiban in the management of acute coronary syndromes in the hospital setting. An analysis based on the PRISM PLUS trial." Eur Heart J 20(17):1253-1260
57. Szucs TD, Bertel O, Darioli R, Gutzwiller F, Mordasini R (2000) "Pharmacoeconomic evaluation of pravastatin in coronary secondary prevention in patients with myocardial infarct or unstable angina pectoris. An analysis based on the LIPID study." Schweiz Rundschau Med Prax 89(18):745-752
58. Waters DD, Axar RR (1997) "Low molecular-weight heparins for unstable angina: a better mousetrap?" Circulation 96:3-5
59. Weintraub WS, Benard J, Mauldin PD, et al (1995) "Declining resource utilization in interventional cardiology?" Am J Med Care 1:58-63
60. Weintraub WS, Culler S, Boccuzzi SJ, Cook JR, Kosinski AS, Cohen DJ, Burnette J (1999) "Economic impact of GPIIB/IIIA blockade after high-risk angioplasty: results from the RESTORE trial. Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis." J Am Coll Cardiol 34(4):1061-1066
61. Yusuf S, Peto R, Lewis J, et al (1985) "Beta blocker during and after myocardial infarction: an overview of the randomised trials." Prog Cardiovasc Dis 27:335-377
62. Zimmerman J, Fromm R, Meyer D, et al (1999) "Diagnostic Marker Cooperative Study for the diagnosis of myocardial infarction." Circulation 99:1671-1677